Merck, a leading science and technology company, announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology… read more.
BeiGene, Ltd., a global oncology company that will change its name to BeOne Medicines Ltd., announced it will share 23 abstracts featuring new data across its hematology and… read more.
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending the conditional marketing authorization of… read more.
Presented at ESTRO 2025, which gathered a record attendance of 7,908 participants this week in Vienna, Austria, a 10-year study, involving over 4,000 UK patients, confirms that a… read more.
Astellas Pharma Incwill present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –… read more.
Eisai Co., Ltd. announced the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which… read more.
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical… read more.
Innate Pharma SA announced that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking… read more.
Europe faces limited supplies of medicines containing radioisotopes which are used to diagnose or treat cancer, according to EU-level and national drug regulators. Experts say European countries should… read more.
Gilead Sciences, Inc. (will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30… read more.
Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma (MM)…. read more.
2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. “The breadth of our oncology and hematology portfolio – anchored by… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
